BR112015031171A2 - obtenção de um ligante terapêutico melhorado - Google Patents
obtenção de um ligante terapêutico melhoradoInfo
- Publication number
- BR112015031171A2 BR112015031171A2 BR112015031171A BR112015031171A BR112015031171A2 BR 112015031171 A2 BR112015031171 A2 BR 112015031171A2 BR 112015031171 A BR112015031171 A BR 112015031171A BR 112015031171 A BR112015031171 A BR 112015031171A BR 112015031171 A2 BR112015031171 A2 BR 112015031171A2
- Authority
- BR
- Brazil
- Prior art keywords
- ligand
- atoms
- binding site
- obtaining
- improved therapeutic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Computing Systems (AREA)
- Evolutionary Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310544.0A GB201310544D0 (en) | 2013-06-13 | 2013-06-13 | Obtaining an improved therapeutic ligand |
| PCT/EP2014/062478 WO2014198951A2 (en) | 2013-06-13 | 2014-06-13 | Obtaining an improved therapeutic ligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015031171A2 true BR112015031171A2 (pt) | 2017-07-25 |
Family
ID=48914497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015031171A BR112015031171A2 (pt) | 2013-06-13 | 2014-06-13 | obtenção de um ligante terapêutico melhorado |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160125124A1 (https=) |
| EP (1) | EP3008648B1 (https=) |
| JP (1) | JP6484612B2 (https=) |
| KR (1) | KR20160019504A (https=) |
| CN (1) | CN105308602B (https=) |
| AU (1) | AU2014280055A1 (https=) |
| BR (1) | BR112015031171A2 (https=) |
| CA (1) | CA2914726A1 (https=) |
| CL (1) | CL2015003591A1 (https=) |
| GB (1) | GB201310544D0 (https=) |
| HK (1) | HK1218579A1 (https=) |
| MX (1) | MX2015016822A (https=) |
| RU (1) | RU2016100234A (https=) |
| SG (2) | SG11201510084TA (https=) |
| WO (1) | WO2014198951A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296732A (en) | 2020-03-27 | 2022-11-01 | UCB Biopharma SRL | Autonomous knob domain peptides |
| CN113380320B (zh) * | 2021-07-01 | 2022-03-15 | 中国海洋大学 | 基于阳性化合物残基贡献相似度的分子对接结果筛选方法 |
| CN115708166A (zh) * | 2021-08-20 | 2023-02-21 | 北京望石智慧科技有限公司 | 一种药物分子设计方法、装置、电子设备及存储介质 |
| CN114530215B (zh) * | 2022-02-18 | 2023-03-28 | 北京有竹居网络技术有限公司 | 设计配体分子的方法和装置 |
| CN115171774A (zh) * | 2022-05-17 | 2022-10-11 | 慧壹科技(上海)有限公司 | 一种抗体/大分子药物的亲和力改造系统和方法 |
| CN121712809A (zh) | 2023-07-03 | 2026-03-20 | Ucb生物制药有限责任公司 | 工程化的aav衣壳蛋白 |
| GB202314896D0 (en) | 2023-09-28 | 2023-11-15 | UCB Biopharma SRL | Knob domain proteins |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| US5642292A (en) | 1992-03-27 | 1997-06-24 | Akiko Itai | Methods for searching stable docking models of biopolymer-ligand molecule complex |
| GB0011818D0 (en) * | 2000-05-16 | 2000-07-05 | Inpharmatica Ltd | Lead molecule generation |
| US20020025535A1 (en) | 2000-06-15 | 2002-02-28 | Diller David J. | Prioritization of combinatorial library screening |
| AU2001279973A1 (en) | 2000-08-21 | 2002-03-04 | Ribotargets Limited | Computer-based modelling of ligand/receptor structures |
| JP2004511803A (ja) * | 2000-10-16 | 2004-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | バニロイド受容体についての改良リガンド結合アッセイ |
| AU2002246737B2 (en) * | 2000-12-29 | 2007-03-01 | Savient Pharmaceuticals, Inc. | Specific human antibodies for selective cancer therapy |
| US20030148391A1 (en) * | 2002-01-24 | 2003-08-07 | Salafsky Joshua S. | Method using a nonlinear optical technique for detection of interactions involving a conformational change |
| EP1620548A2 (en) | 2003-05-07 | 2006-02-01 | Duke University | Protein design for receptor-ligand recognition and binding |
| US20060105390A1 (en) * | 2003-10-29 | 2006-05-18 | Yi Zhang | Method of characterizing heterogeneity in receptor-ligand interactions and related method of assay signal histogram transformation |
| JP2005181104A (ja) * | 2003-12-19 | 2005-07-07 | Hitachi Ltd | 高精度ドッキングスコアリング方法 |
| JP4719223B2 (ja) | 2005-03-11 | 2011-07-06 | シュレディンガー エルエルシー | 結合親和性を推定するための予測的スコア関数 |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| US20090006040A1 (en) | 2007-05-24 | 2009-01-01 | Peter Hrnciar | Systems and Methods for Representing Protein Binding Sites and Identifying Molecules with Biological Activity |
| EP2216429A4 (en) | 2007-11-12 | 2011-06-15 | In Silico Sciences Inc | SILICO SCREENING SYSTEM AND SILICO SCREENING METHOD |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| JPWO2010110288A1 (ja) * | 2009-03-24 | 2012-09-27 | 株式会社カネカ | 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
| US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| ME02734B (me) | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
-
2013
- 2013-06-13 GB GBGB1310544.0A patent/GB201310544D0/en not_active Ceased
-
2014
- 2014-06-13 SG SG11201510084TA patent/SG11201510084TA/en unknown
- 2014-06-13 WO PCT/EP2014/062478 patent/WO2014198951A2/en not_active Ceased
- 2014-06-13 JP JP2016518523A patent/JP6484612B2/ja active Active
- 2014-06-13 SG SG10201707917UA patent/SG10201707917UA/en unknown
- 2014-06-13 AU AU2014280055A patent/AU2014280055A1/en not_active Abandoned
- 2014-06-13 CN CN201480033334.7A patent/CN105308602B/zh active Active
- 2014-06-13 HK HK16106512.8A patent/HK1218579A1/zh unknown
- 2014-06-13 BR BR112015031171A patent/BR112015031171A2/pt not_active IP Right Cessation
- 2014-06-13 MX MX2015016822A patent/MX2015016822A/es unknown
- 2014-06-13 KR KR1020167000533A patent/KR20160019504A/ko not_active Withdrawn
- 2014-06-13 US US14/897,459 patent/US20160125124A1/en not_active Abandoned
- 2014-06-13 EP EP14729693.3A patent/EP3008648B1/en active Active
- 2014-06-13 RU RU2016100234A patent/RU2016100234A/ru not_active Application Discontinuation
- 2014-06-13 CA CA2914726A patent/CA2914726A1/en not_active Abandoned
-
2015
- 2015-12-10 CL CL2015003591A patent/CL2015003591A1/es unknown
-
2020
- 2020-03-18 US US16/823,055 patent/US11942188B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016527481A (ja) | 2016-09-08 |
| CN105308602A (zh) | 2016-02-03 |
| CL2015003591A1 (es) | 2016-08-05 |
| EP3008648B1 (en) | 2023-05-10 |
| US20160125124A1 (en) | 2016-05-05 |
| RU2016100234A (ru) | 2018-02-06 |
| GB201310544D0 (en) | 2013-07-31 |
| RU2016100234A3 (https=) | 2018-03-23 |
| SG11201510084TA (en) | 2016-01-28 |
| CA2914726A1 (en) | 2014-12-18 |
| US20210005277A1 (en) | 2021-01-07 |
| JP6484612B2 (ja) | 2019-03-13 |
| EP3008648A2 (en) | 2016-04-20 |
| SG10201707917UA (en) | 2017-10-30 |
| MX2015016822A (es) | 2016-04-13 |
| WO2014198951A3 (en) | 2015-08-27 |
| CN105308602B (zh) | 2019-09-27 |
| AU2014280055A1 (en) | 2016-01-28 |
| HK1218579A1 (zh) | 2017-02-24 |
| US11942188B2 (en) | 2024-03-26 |
| WO2014198951A2 (en) | 2014-12-18 |
| KR20160019504A (ko) | 2016-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015031171A2 (pt) | obtenção de um ligante terapêutico melhorado | |
| MX2015012437A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| BR112014030110A8 (pt) | métodos e aparelhos para coletar informação de usuário distribuída para impressões de mídia e termos de pesquisa | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| BR112018071026A2 (pt) | macromoléculas fotoativas e usos das mesmas | |
| BR112014025520A2 (pt) | método para estimar características de uma formação | |
| BR112016001611A2 (pt) | Anticorpos multiespecíficos, anticorpos ativáveis multiespecíficos e métodos de utilização dos mesmos | |
| BR112014027165A2 (pt) | antagonistas de st2l e métodos de uso | |
| EP3640341A3 (en) | Assays to determine dna methylation and dna methylation markers of cancer | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| BR112019009256A2 (pt) | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo | |
| EP3004394A4 (en) | TESTS, METHODS AND KITS FOR ANALYZING SENSITIVITY AND RESISTANCE TO ANTICROBIAL AGENTS, PREDICTING THE PROGNOSIS OF A CANCER PATIENTS AND FOR PERSONALIZED TREATMENT STRATEGIES | |
| BR112015010220A2 (pt) | métodos de utilização de biomarcadores para tratamento de câncer | |
| BR112015004631A2 (pt) | marcadores genéticos de resistência à mastite | |
| MX352373B (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
| MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| MX374415B (es) | Composiciones y métodos para identificar un riesgo de cáncer en un sujeto. | |
| BR112015020061A2 (pt) | tratamento de câncer à base de estratificação de caix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |